Hyperlipoproteinemia Type IV

A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.

Also Known As:

Type IV, Hyperlipoproteinemia; Carbohydrate Inducible Hyperlipemia; Carbohydrate-Inducible Hyperlipemia; Familial Hyperlipoproteinemia Type 4; Familial Type IV Hyperlipoproteinemia; Hyper prebeta lipoproteinemia; Hyperlipoproteinemia, Type IV; Carbohydrate Inducible Hyperlipemias; Carbohydrate-Inducible Hyperlipemias; Familial Hypertriglyceridemia; Hyperlipemia, Carbohydrate Inducible; Hyperlipemia, Carbohydrate-Inducible; Hyperlipemias, Carbohydrate Inducible; Hyperlipemias, Carbohydrate-Inducible; Hyperlipoproteinemias, Type IV; Inducible Hyperlipemia, Carbohydrate; Inducible Hyperlipemias, Carbohydrate; Type IV Hyperlipoproteinemia; Type IV Hyperlipoproteinemias; Hyperprebetalipoproteinemia; Hypertriglyceridemia, Familial

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 960
- Inborn Genetic Diseases: 12342
  - Inborn Errors Metabolism: 1183
    - Inborn Errors Lipid Metabolism
      - Hyperlipoproteinemia Type IV: 241
Nutritional and Metabolic Diseases: 15
- Metabolic Diseases: 10634
  - Inborn Errors Metabolism: 1183
    - Inborn Errors Lipid Metabolism
      - Hyperlipoproteinemia Type IV: 241
  - Lipid Metabolism Disorders: 987
    - Dyslipidemias: 18780
      - Hyperlipidemias: 16526
        Hypertriglyceridemia: 8493
        Hyperlipoproteinemia Type IV: 241
        Hyperlipoproteinemias: 1409
        Hyperlipoproteinemia Type IV: 241
    - Inborn Errors Lipid Metabolism
      - Hyperlipoproteinemia Type IV: 241

Mahmoud A Abuissa Qadan Selected Research

Mahmoud A Abuissa Qadan Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure